Bectas Therapeutics Awarded $2.75M CPRIT Product Development Seed Grant
Bectas Therapeutics was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT). These funds will support the pre-clinical development of Bectas’ first-in-class precision antibody and patient selection biomarker that together are designed to overcome resistance to existing cancer treatments for over 200,000 patients per year. Bectas received the […]